[go: up one dir, main page]

WO2010000364A8 - Dérivé de pyrrolopyridinylpyrimidin-2-ylamine - Google Patents

Dérivé de pyrrolopyridinylpyrimidin-2-ylamine Download PDF

Info

Publication number
WO2010000364A8
WO2010000364A8 PCT/EP2009/004013 EP2009004013W WO2010000364A8 WO 2010000364 A8 WO2010000364 A8 WO 2010000364A8 EP 2009004013 W EP2009004013 W EP 2009004013W WO 2010000364 A8 WO2010000364 A8 WO 2010000364A8
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolopyridinylpyrimidin
ylamine derivatives
ylamine
derivatives
cell
Prior art date
Application number
PCT/EP2009/004013
Other languages
German (de)
English (en)
Other versions
WO2010000364A1 (fr
Inventor
Margarita Wucherer-Plietker
David Bruge
Dirk Finsinger
Ulrich Graedler
Dieter Dorsch
Christina Esdar
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2011515149A priority Critical patent/JP5587874B2/ja
Priority to US13/002,168 priority patent/US8420820B2/en
Priority to BRPI0913832A priority patent/BRPI0913832A2/pt
Priority to EP09772064.3A priority patent/EP2291375B1/fr
Priority to AU2009266090A priority patent/AU2009266090B2/en
Priority to MX2010013919A priority patent/MX2010013919A/es
Priority to CA2729725A priority patent/CA2729725C/fr
Priority to CN2009801210428A priority patent/CN102056926B/zh
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to EA201100125A priority patent/EA201100125A1/ru
Priority to ES09772064.3T priority patent/ES2564204T3/es
Publication of WO2010000364A1 publication Critical patent/WO2010000364A1/fr
Priority to IL210406A priority patent/IL210406A/en
Publication of WO2010000364A8 publication Critical patent/WO2010000364A8/fr
Priority to ZA2011/00876A priority patent/ZA201100876B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Les composés de formule (I), dans laquelle X, R1, R2, R3, R4 et R6 ont les significations données à la revendication 1, sont des inhibiteurs de la prolifération cellulaire/vitalité cellulaire et peuvent être utilisés pour le traitement de tumeurs.
PCT/EP2009/004013 2008-07-03 2009-06-04 Dérivé de pyrrolopyridinylpyrimidin-2-ylamine WO2010000364A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA2729725A CA2729725C (fr) 2008-07-03 2009-06-04 Derive de pyrrolopyridinylpyrimidin-2-ylamine
BRPI0913832A BRPI0913832A2 (pt) 2008-07-03 2009-06-04 derivados de pirrolopiridinilpirimidin-2-ilamina
EP09772064.3A EP2291375B1 (fr) 2008-07-03 2009-06-04 Dérivé de pyrrolopyridinylpyrimidin-2-ylamine
AU2009266090A AU2009266090B2 (en) 2008-07-03 2009-06-04 Pyrrolopyridinylpyrimidin-2-ylamine derivatives
MX2010013919A MX2010013919A (es) 2008-07-03 2009-06-04 Derivados de pirrolopiridinil-pirimidin-2-il-amina.
JP2011515149A JP5587874B2 (ja) 2008-07-03 2009-06-04 ピロロピリジニルピリミジン−２−イルアミン誘導体
ES09772064.3T ES2564204T3 (es) 2008-07-03 2009-06-04 Derivados de pirrolopiridinil-pirimidin-2-il-amina
CN2009801210428A CN102056926B (zh) 2008-07-03 2009-06-04 吡咯并吡啶基嘧啶-2-基胺衍生物
EA201100125A EA201100125A1 (ru) 2008-07-03 2009-06-04 Производные пирролопиридинилпиримидин-2-иламина
US13/002,168 US8420820B2 (en) 2008-07-03 2009-06-04 Pyrrolopyridinylpyrimidin-2-ylamine derivatives
IL210406A IL210406A (en) 2008-07-03 2010-12-30 Derivatives of pyrolopyridinylpyrimidine-2-illamine
ZA2011/00876A ZA201100876B (en) 2008-07-03 2011-02-02 Pyrrolopyridinylpyrimidin-2-ylamine derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008031517.6 2008-07-03
DE102008031517A DE102008031517A1 (de) 2008-07-03 2008-07-03 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE1020080315176 2008-07-03

Publications (2)

Publication Number Publication Date
WO2010000364A1 WO2010000364A1 (fr) 2010-01-07
WO2010000364A8 true WO2010000364A8 (fr) 2011-01-06

Family

ID=40849173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/004013 WO2010000364A1 (fr) 2008-07-03 2009-06-04 Dérivé de pyrrolopyridinylpyrimidin-2-ylamine

Country Status (16)

Country Link
US (1) US8420820B2 (fr)
EP (1) EP2291375B1 (fr)
JP (2) JP5587874B2 (fr)
KR (1) KR20110027835A (fr)
CN (1) CN102056926B (fr)
AR (1) AR072792A1 (fr)
AU (1) AU2009266090B2 (fr)
BR (1) BRPI0913832A2 (fr)
CA (1) CA2729725C (fr)
DE (1) DE102008031517A1 (fr)
EA (1) EA201100125A1 (fr)
ES (1) ES2564204T3 (fr)
IL (1) IL210406A (fr)
MX (1) MX2010013919A (fr)
WO (1) WO2010000364A1 (fr)
ZA (1) ZA201100876B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102009060174A1 (de) * 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
SG184832A1 (en) 2010-04-16 2012-11-29 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
WO2011143459A1 (fr) * 2010-05-12 2011-11-17 Abbott Laboratories Pyrrolopyridine et pyrrolopyrimidine inhibitrices de kinases
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
DE102011105469A1 (de) 2011-06-24 2012-12-27 Merck Patent Gmbh 7-Azaindolderivate
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
CA2903293C (fr) * 2013-03-15 2020-10-13 Plexxikon Inc. Composes heterocycliques et leurs utilisations
CA2933767C (fr) 2013-12-17 2018-11-06 Pfizer Inc. Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituees et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituees en tant qu'inhibiteurs de la lrrk2
CN107278202A (zh) * 2015-01-23 2017-10-20 融合生命科学公司 用于治疗炎症和癌症的杂环itk抑制剂
CN106432246B (zh) * 2015-08-05 2020-07-07 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3350178B1 (fr) 2015-09-14 2021-10-20 Pfizer Inc. Nouveaux dérivés imidazo [4,5-c]quinoline et imidazo [4,5-c][1,5]naphthyridine utilisés comme inhibiteurs de lrrk2
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
EP3694855A1 (fr) 2017-10-13 2020-08-19 Plexxikon Inc. Formes solides d'un composé pour la modulation de kinases
EP3706086A4 (fr) 2017-10-31 2021-07-21 Alise Devices, S.L. Procédé de fabrication d'éléments optiques de sécurité documentaire personnalisés et élément ainsi obtenu
PT4043460T (pt) * 2018-04-24 2024-09-10 Merck Patent Gmbh Compostos antiproliferação e utilizações dos mesmos
CA3119988A1 (fr) 2018-11-16 2020-05-22 California Institute Of Technology Inhibiteurs d'erk et leurs utilisations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CN101676285A (zh) * 2004-03-30 2010-03-24 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
CA2608333A1 (fr) * 2005-05-16 2006-11-23 Irm Llc Composes et compositions en tant qu'inhibiteurs de proteine kinase
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate

Also Published As

Publication number Publication date
CN102056926B (zh) 2013-10-16
US8420820B2 (en) 2013-04-16
AU2009266090B2 (en) 2014-04-03
CN102056926A (zh) 2011-05-11
EP2291375B1 (fr) 2016-01-06
ES2564204T3 (es) 2016-03-18
JP2014240397A (ja) 2014-12-25
BRPI0913832A2 (pt) 2015-10-20
JP5587874B2 (ja) 2014-09-10
CA2729725C (fr) 2016-11-08
EA201100125A1 (ru) 2011-08-30
WO2010000364A1 (fr) 2010-01-07
AU2009266090A1 (en) 2010-01-07
DE102008031517A1 (de) 2010-01-07
MX2010013919A (es) 2011-02-21
CA2729725A1 (fr) 2010-01-07
AR072792A1 (es) 2010-09-22
JP5955902B2 (ja) 2016-07-20
IL210406A (en) 2014-11-30
IL210406A0 (en) 2011-03-31
EP2291375A1 (fr) 2011-03-09
ZA201100876B (en) 2011-10-26
KR20110027835A (ko) 2011-03-16
JP2011526260A (ja) 2011-10-06
US20110218198A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
WO2010000364A8 (fr) Dérivé de pyrrolopyridinylpyrimidin-2-ylamine
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2010003368A (es) Derivados de imidazol.
WO2009046841A3 (fr) Dérivés de pipéridine et de pipérazine
MX2011011488A (es) Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina.
WO2010038086A8 (fr) Nouveaux composés
MX2009012708A (es) Derivados de piridazinona.
WO2010003475A3 (fr) Nouveaux dérivés de pyrrolidine utilisés comme inhibiteurs de la metap-2
MX352975B (es) Piridina y derivados de pirazina.
UA104731C2 (ru) Ингибиторы р38 мар-киназ
MX2009013077A (es) Derivados dde benzoxazolona.
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
WO2012104007A3 (fr) Dérivés de 7-azaindole
MY149957A (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2008128072A3 (fr) Inhibiteurs de la kinase axl
MX2009008798A (es) Derivados de iminipiridina y sus usos como microbicidas.
PH12012501905A1 (en) Quinoline derivatives and their use as fungicides
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
UA95934C2 (ru) Производные пиридиазинона для лечения опухолей
MX340714B (es) Inhibidores de hsp90.
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
ZA200701137B (en) Triazolophthalazines
MX2008001538A (es) Aril piridinas y metodos para su uso.
WO2011101069A3 (fr) Hétarylaminonaphtyridines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980121042.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09772064

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009772064

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/013919

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2011515149

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2729725

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 210406

Country of ref document: IL

Ref document number: 13002168

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009266090

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 201100125

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20117002711

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 544/KOLNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009266090

Country of ref document: AU

Date of ref document: 20090604

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0913832

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101231